The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jul 2011
Randomized Controlled Trial Multicenter StudyEfficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma. ⋯ The results of this study indicate that omalizumab is an effective treatment option for patients with CU with IgE autoantibodies against TPO who are refractory to conventional treatment.